Daiichi Sankyo Company, Limited (Hereafter, Daiichi Sankyo) And Gustave Roussy Announced A Multi-Year, Multi-Study Research Collaboration To Enrich And Further Enable The Development Of Ds-1062 And Patritumab Deruxtecan (U3-1402), Two Of Daiichi Sankyo&Rsquo;S Lead Dxd Antibody Drug Conjugates (Adcs), In Lung And Breast Cancer.The Collaboration Will Focus On Clinical And Translational Research, Including Potential Combination Strategies For Ds-1062, A Trop2 Directed Dxd Adc, In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc), And For Patritumab Deruxtecan, A Her3 Directed Dxd Adc, In Patients With Metastatic Breast Cancer.&Ldquo;We Look Forward To Engaging And Collaborating With The Deep Expertise And Cutting-Edge Oncology Research Capabilities Of Gustave Roussy, The Premier European Cancer Center, To Further Advance Clinical Development Of Ds-1062 And Patritumab Deruxtecan,&Rdquo; Said Antoine Yver, Md, Msc, Aihp, Acca Paris, Global Head, Oncology R&Amp;D, Daiichi Sankyo. &Ldquo;This Innovative Research Program Includes Two Precision-Medicine Rich Phase 2 Trials Designed With An Adaptive Approach To Help Determine Which Patients Are Most Likely To Benefit From Our Adcs With Optimal Speed And Efficiency. Combination Therapy Strategies Will Also Be Explored In Other Studies.&Rdquo;&Ldquo;This Partnership Is Strategic For Gustave Roussy And It Brings Together All The Skills Which Are Essential For Top Quality Research In Oncology. Launching Clinical Trials To Test Two Promising Molecules In Advanced Non-Small Cell Lung Cancer And Metastatic Breast Cancer Is Essential For Diseases Which Unfortunately Have An Increasing Incidence And For Which There Is An Urgent Need To Make Progress,&Rdquo; Said Prof. Jean-Charles Soria, General Director Of Gustave Roussy. "It Is By Pushing The Boundaries Of Innovation That We Will Further Improve The Quality Of Care For Our Patients."
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!